A5085522760- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Health Systems, Economic Evaluations, Quality of Life
- Dermatology and Skin Diseases
- Systemic Lupus Erythematosus Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Musculoskeletal Disorders and Rehabilitation
- Bone and Joint Diseases
- Pharmaceutical studies and practices
- Diversity and Career in Medicine
- Hepatitis B Virus Studies
- Peripheral Neuropathies and Disorders
- Biosimilars and Bioanalytical Methods
- Cytokine Signaling Pathways and Interactions
- Chronic Lymphocytic Leukemia Research
- Animal Virus Infections Studies
- Innovations in Medical Education
- Interprofessional Education and Collaboration
- Mental Health and Patient Involvement
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
University of Oxford
2017-2025
Nuffield Orthopaedic Centre
2017-2025
Oxford University Hospitals NHS Trust
2021-2024
Oxford Biomedical Research
2022-2024
Oxford BioMedica (United Kingdom)
2022-2024
Oxford Brookes University
2024
NIHR Oxford Musculoskeletal Biomedical Research Centre
2017-2023
British Society for Rheumatology
2017-2023
Hospital de Clínicas de Porto Alegre
2022
University of Leeds
2011-2021
Objective To update the 2009 Group for Research and Assessment of Psoriasis Psoriatic Arthritis (GRAPPA) treatment recommendations spectrum manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologists, dermatologists, PsA drafted overarching principles management PsA, based on consensus achieved at face‐to‐face meetings via online surveys. We conducted literature reviews regarding key domains (arthritis, spondylitis, enthesitis, dactylitis, skin disease,...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence these recommendations was only of indirect nature. These were re-evaluated light new insights. Based on results a systematic literature review expert opinion, task force rheumatologists, dermatologists, patients health professional developed an update 2012 recommendations. underwent intensive discussions, site voting subsequent anonymous electronic levels agreement with each item....
To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With recent therapeutic advances, this is now a goal treatment and may represent measure to compare therapies. It defines satisfactory state of rather than change, encompasses all aspects the disease.40 patient profiles were sampled from an observational PsA database. Sixty experts in classified these as MDA or not. A consensus > =70% was accepted, identifying 13 MDA. Summary statistics created possible cut-off...
Objective To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between American College Rheumatology ( ACR ) National Psoriasis Foundation NPF ). Methods We identified critical outcomes in PsA clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed systematic literature review to summarize evidence supporting benefits harms available therapies...
Magnetic resonance imaging (MRI) is increasingly used to detect sacroiliitis earlier. This study was undertaken investigate what proportion of patients with MRI-evident develop ankylosing spondylitis (AS) in the long term and whether there are predictors outcome.Consecutive undiagnosed early inflammatory back pain (IBP) (of <2 years' duration) were assessed clinically radiologically. Baseline assessments included fat-suppressed MRI sequences sacroiliac joints lumbar spine that scored for...
Abstract Objective To evaluate the efficacy of infliximab in HLA–B27–positive patients with magnetic resonance imaging (MRI)–determined early sacroiliitis, using both clinical and MRI assessments. Methods Forty recent‐onset inflammatory back pain, as assessed by Calin criteria, HLA–B27 positivity, disease activity measured Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pain morning stiffness, sacroiliac joint bone edema were randomized a double‐blind manner to receive 5 mg/kg...
Plain language summary available online
Linked Comment:Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online
MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab management axial manifestations psoriatic (PsA).This phase 3b, double-blind, placebo-controlled, multi-centre 52-week included patients (≥18 years) diagnosed PsA and classified by ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria, spinal pain Visual Analogue Score ≥40/100 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score...
BackgroundBimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy safety of bimekizumab with placebo over 16 weeks in patients active psoriatic arthritis previous inadequate response or intolerance to tumour necrosis factor-α (TNFα) inhibitors.MethodsBE COMPLETE was phase 3, multicentre, randomised, double-blind, placebo-controlled trial conducted across 92 sites (including hospitals, clinics, research centres) 11...
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17A and IL-17F. We assessed the efficacy safety of bimekizumab in patients with active psoriatic arthritis who were naive to biologic disease-modifying antirheumatic drugs (DMARDs).BE OPTIMAL was 52-week, phase 3, multicentre, randomised, double-blind, placebo-controlled, reference (adalimumab) trial done at 135 sites (hospitals, clinics, doctors' offices, research centres) 14 countries. Eligible 18 years or...
BackgroundImmunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses S1 receptor-binding domain (S1-RBD) SARS-CoV-2 spike protein compared with uninterrupted in patients immune-mediated inflammatory diseases.MethodsWe did an open-label, prospective, two-arm, parallel-group, multicentre, randomised, controlled, superiority trial...
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) prior inadequate response/intolerance to tumour necrosis factor inhibitors. Methods Patients completing the 16-week phase III double-blind, placebo-controlled BE COMPLETE ( NCT03896581 ) study entered open-label extension, VITAL NCT04009499 ). All received 160 mg every 4 weeks. Safety are reported week 52. Results A total 347/400 (86.8%) completed 52, exposure-adjusted incidence...
cDNA prepared from the single-stranded circular RNA genome of hepatitis delta virus was cloned in lambda gt11 by using liver an infected woodchuck. From sequence overlapping clones, we assembled full 1,679 nucleotides. The indicated exceptional ability for intramolecular base pairing, yielding a rod structure with at least 70% bases paired and predicted free energy -805 kcal (-3,368 kJ)/mol. Three clones contained sequences that were not only expressed as fusion proteins beta-galactosidase...
Abstract Objective New criteria for minimal disease activity (MDA) in psoriatic arthritis (PsA) have been developed. The aim is to provide further validation of these using data obtained interventional trials with infliximab, a drug proven efficacy PsA. Methods were from patients phase II and III infliximab studies In both studies, active PsA treated (5 mg/kg) or placebo followed by period treatment infliximab. Between‐group comparisons terms those achieving MDA the relationship American...